#USA #Ankeny #Proliant Health #AlbufreeDX #Recombinant Albumin

Proliant Health & Biologicals Redefines Albumin with AlbufreeDX

In an innovative leap for the life sciences sector, Proliant Health & Biologicals has officially announced the commercial launch of AlbufreeDX, a recombinant human albumin. This groundbreaking product aims to meet the rising demand for highly efficient, non-animal derived ingredients used in diagnostics and life sciences applications. With a strong commitment to quality and consistency, Proliant has established itself as a global leader in purified proteins for over two decades.

A Game-Changer in Diagnostics and Biotechnology

Founded in Ankeny, Iowa, Proliant operates with manufacturing facilities located in the United States and New Zealand. The company specializes in developing and producing high-quality albumin and other purified proteins. Albumin has wide-ranging applications in diagnostics, biopharmaceutical manufacturing, and various research processes. Its ability to stabilize proteins and enhance the performance and reproducibility of tests has made it indispensable across these fields.

As diagnostic tests evolve toward higher sensitivity and throughput, the need for raw materials exhibiting exceptional homogeneity and purity becomes even more critical. Traditional animal-derived or human albumins can lead to additional testing requirements, traceability challenges, and increased regulatory complexity. AlbufreeDX aims to address these issues by providing a seamless alternative.

Simplifying Regulatory Compliance

Christopher Warner, Proliant’s Vice President of Research and Development, notes that diagnostic device manufacturers are increasingly favoring options that eliminate animal or human-derived ingredients in their products. "AlbufreeDX supports this trend by simplifying compliance with global standards and the regulations governing in vitro diagnostic medical devices. This helps companies meet their commitments to environmental, social, and governance (ESG) goals."

The recombinant albumin is derived through precision fermentation, ensuring high purity, reliable performance, and excellent batch-to-batch reproducibility. AlbufreeDX is particularly well-suited for applications such as protein stabilization, surface blocking, and formulating reagents, especially where minimizing variability and eliminating animal-derived pathogen risks are crucial.

Meeting Customer Needs with Innovative Solutions

Christopher Detzel, the CEO, remarked, "Our product range has evolved alongside our customers' needs. AlbufreeDX represents a natural extension of our strong portfolio, offering an alternative to animal-derived albumin while ensuring the consistency, reliability, and scalable production our clients expect."

The introduction of AlbufreeDX marks another significant addition to Proliant's expanding life sciences product lineup. Future products are expected to include AlbufreeTX, aimed at cell culture applications, and AlbufreeCGT, designed to support new cell and gene therapy processes.

For those looking to learn more about this innovative new product and its applications, further information can be found on Proliant’s official website. Proliant aims to continue leading the market by providing solutions that advance diagnostics while aligning with modern consumer needs for sustainable and ethical practices in biotechnology.